CAS: 22033-87-0; (8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-Methylheptan-2-yl)-1,2,6,7,8,9,10,11,12,13,14,15,16,17-Tetradecahydro-3H-Cyclopenta[a]Phenanthren-3-One Oxime

上下游产品

CAS号601-57-0 4-胆甾烯-3-酮 | CAS号601-57-0 4-胆甾烯-3-酮 | CAS号21002-96-0 4-Aza-A-hom°Cho...

📜4-胆甾烯-3-酮置于potassium Dihydrogenphosphate,盐酸羟胺体系中,用 乙醇 用作溶剂,化学反应 1.0H,反应生成奥利索西
参考文献:Convenient Preparation Of A-Ring Fused Pyridines From Steroidal Enamides
标题:Convenient Preparation Of A-Ring Fused Pyridines From Steroidal Enamides
摘要:A Facile Strategy For The Preparation Of A-Ring Fused Pyridosteroids Has Been Accomplished In High Yields By The Reaction Of Vilsmeier Reagent (Chloromethyleneiminium Salt) With Steroidal A-Ring Enamides (2-And 3-Ene) Under Thermal Conditions. The Structure Of 6'-Chloro-5 Alpha-Cholest [3,2-B]Pyridine Was Determined By X-Ray Analysis. (C) 2008 Elsevier Inc. All Rights Reserved.
Doi:10.1016/j.Steroids.2008.04.016

专利信息

专利号:US-12358903-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; FARAND JULIE; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-11739065-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-2023047961-A1
优先权日:2019-12-03
标 题 :The cholesterol-syntesis intermediates for treatment demyelinating disorders
发明人：BERGHOFF STEFAN; SAHER GESINE
权利人:MAX PLANCK GESELLSCHAFT
摘要:The present invention relates to a cholesterol-synthesis intermediate as pharmaceutically active agent and/or pharmaceutical composition comprising the cholesterol-synthesis intermediate optionally together with one or two further pharmaceutically active agent(s) for use in the prophylaxis and/or treatment of demyelinating disorders/diseases, in particular multiple sclerosis.